FDA approvals of generic drugs: Impact on the diversion of opioid analgesics with a potential for abuse

James A. Inciardi, PhD; Hilary L. Surratt, PhD; Yamilka Stivers, BA; Theodore J. Cicero, PhD

doi:10.5055/jom.2009.0009

Authors

James A. Inciardi, PhD
Hilary L. Surratt, PhD
Yamilka Stivers, BA
Theodore J. Cicero, PhD

DOI:

https://doi.org/10.5055/jom.2009.0009

Keywords:

diversion, oxycodone, opioids, generics, fentanyl

Abstract

Generic drugs account for half of all prescription drug purchases in the United States. Although they are bioequivalent to their branded counterparts, they are typically sold at substantial discounts from the branded price. Given this, the purpose of this analysis is to examine the impact of the introduction of generic forms of selected opioids on their diversion to the illicit marketplace. The analgesics in this analysis include oxycodone ER (extended release), and the fentanyl transdermal patch. The data were collected through a postmarketing surveillance initiative supported by the Researched Abuse Diversion and Addiction-Related Surveillance (RADARS®) System risk management program, gathered on a quarterly basis from a national sample of police and regulatory agencies. The results indicate that with oxycodone ER and the fentanyl transdermal patch, the diversion of their generic formulations occurs less often than that of the branded products, and that the introduction of the generic formulations did not significantly increase the overall levels of diversion during the period covered by this analysis. Although diversion did not increase in the short-term, the need for longer term monitoring appears warranted.

Author Biographies

James A. Inciardi, PhD

University of Delaware, Coral Gables, Florida.

Hilary L. Surratt, PhD

University of Delaware, Coral Gables, Florida.

Yamilka Stivers, BA

University of Delaware, Coral Gables, Florida.

Theodore J. Cicero, PhD

Washington University School of Medicine, St. Louis, Missouri.

References

Chambers CD, Inciardi JA, Petersen DM, et al.: Chemical Dependencies: Patterns, Costs, and Consequences. Athens, OH: Ohio University Press, 1987.

Chambers CD, Inciardi JA, Siegal HA: Chemical Coping: A Report on Legal Drug Use in the United States. New York: Spectrum Publications, 1975.

Hughes R, Brewin R: The Tranquilizing of America: Pill Popping and the American Way of Life. New York: Harcourt Brace Jovanovich, 1979.

Mondanaro J: Chemically Dependent Women: Assessment and Treatment. Lexington, MA: Lexington Books, 1989.

Weil A, Rosen W: Chocolate to Morphine: Understanding Mind-Active Drugs. Boston: Houghton Mifflin Company, 1983.

Grinspoon L, Hedblom P: The Speed Culture: Amphetamine Use and Abuse in America. Cambridge, MA: Harvard University Press, 1975.

Inciardi JA: Patterns of Methaqualone Abuse. In U.S. Congress ed.): Methaqualone Traffic, Abuse, and Regulation. Washington, DC: U.S. Government Printing Office, 1973: 109-115.

Inciardi JA, Petersen DM, Chambers CD: Methaqualone abuse patterns, diversion paths and adverse reactions. J Fla Med Assoc. 1974; 61: 279-283.

Klee H (ed.): Amphetamine Misuse: International Perspectives on Current Trends. Amsterdam: Harwood Academic Publishers, 1997.

Zacny J, Bigelow G, Compton P, et al.: College on problems of drug dependence taskforce on prescription opioid non-medical use and abuse: Position statement. Drug Alcohol Depend. 2003; 69(3): 215-232.

McCabe SE, Knight JR, Teter CJ, et al.: Non-Medical use of prescription stimulants among US college students: Prevalence and correlates from a national survey. Addiction. 2005; 99(1): 96-106.

McCabe SE, Teter CJ, Boyd CJ: The use, misuse and diversion of prescription stimulants among middle and high school students. Subst Use Misuse. 2004; 39(7): 1095-1116.

McCabe SE, Teter CJ, Boyd CJ, et al.: Nonmedical use of prescription opioids among U.S. college students: Prevalence and correlates from a national survey. Addictive Behav. 2005; 30, 789-805.

Meier B: Pain Killer: A “Wonder” Drug’s Trail of Addiction and Death. Emmaus, PA: Rodale Press, 2003.

National Institute on Drug Abuse: NIDA infoFacts: Methylphenidate (Ritalin). Washington, DC: U.S. Department of Health & Human Services, 2004.

Office of National Drug Control Policy: Press release: U.S. drug prevention, Treatment, enforcement agencies take on “doctor shoppers,” “pill mills,” March 1. Available at www.whitehousedrugpolicy.gov/news/press04/030104.html. Accessed July 25, 2006.

McCarthy M: Prescription drug abuse up sharply in the USA. The Lancet. 2007; 369: 1505-1506.

Substance Abuse and Mental Health Services Administration, & Office of Applied Studies: Results from the 2007 National Survey on Drug Use and Health: National Findings. (Office of Applied Studies, NSDUH). Rockville, MD: Substance Abuse and Mental Health Services Administration, & Office of Applied Studies, 2008.

Substance Abuse and Mental Health Services Administration, & Office of Applied Studies: Treatment Episode Data Set (Teds) 1992-2002: National Admissions to Substance Abuse Treatment Services. DASIS Series: S-23, DHHS Publication No. (SMA) 04-3965. Rockville, MD: Substance Abuse and Mental Health Services Administration, & Office of Applied Studies, 2004.

Substance Abuse and Mental Health Services Administration, & Office of Applied Studies: Benzodiazepines in Drug Abuse-Related Emergency Department Visits: 1995-2002. The DAWN report, 2004. Available at http://dawninfo. samhsa.gov/old_dawn/pubs_94_02/shortreports/files/DAWN_tdr_benzo.pdf. Accessed October 27, 2008.

Cicero TJ, Inciardi JA, Muñoz A: Trends in abuse of OxyContin® and other opioid analgesics in the United States: 2002-2004. Pain. 2005; 6(10): 662-672.

Hench D: Generic OxyContin Worries Authorities. Miami Herald, January 13, 2004.

Drug Enforcement Administration: Drug alert: Generic OxyContin® emerges as new threat. Available at www.dea.gov/concern/generic_oxycodone_factsheetp.html. Accessed April 15, 2004.

Inciardi JA, Surratt HL, Kurtz SP, et al.: Mechanisms of prescription drug diversion among drug-involved club- and streetbased populations. Pain Med. 2007; 8(2): 171-183.

Cicero TJ, Dart RC, Inciardi JA, et al.: The development of a comprehensive risk-management program for prescription opioid analgesics: Researched abuse, diversion and addictionrelated surveillance (RADARS®). Pain Med. 2007; 8(2): 157-170.

Smith MY, Schneider MF, Wentz A, et al.: Quantifying morbidity associated with the abuse and misuse of opioid analgesics: A comparison of two approaches. J Clin Toxicol. 2007; 45(1): 23-30.

Bailey JE, Barton PL, Lezotte D, et al.: The effect of FDA approval of a generic competitor to OxyContin® (oxycodone HCl controlled-release) tablets on the abuse of oxycodone. Drug Alcohol Depend. 2006; 84(2): 182-187.

Compton WM, Volkow ND: Major increases in opioid analgesic abuse in the United States: Concerns and strategies. Drug Alcohol Depend. 2006; 81: 103-107.

CASA (The National Center on Addiction and Substance Abuse at Columbia University): Under the Counter: The Diversion and Abuse of Controlled Prescription Drugs in the U.S. New York: The National Center on Addiction and Substance Abuse at Columbia University, 2005.

Drug Topics: The top 200 prescriptions for 2007 by prescriptions dispensed. Available at www.drugtopics.com/. Accessed April 17, 2007.

Joranson DE, Ryan KM, Gilson AM, et al.: Trends in medical use and abuse of opioid analgesics. J Am Med Assoc. 2000; 283(13): 1710-1714.

Novak S, Nemeth WC, Lawson KA: Trends in medical use and abuse of sustained-release opioid analgesics: A revisit. Pain Med. 2004; 5(1): 59-65.

Katz NP, Adams EH, Benneyan JC, et al.: Foundations of opioid risk management. Clin J Pain. 2007; 23(2): 103-118.

Gilson AM, Joranson DE: U.S. policies relevant to the prescribing of opioid analgesics for the treatment of pain in patients with addictive disease. Clin J Pain. 2002; 18(Suppl. 4): S91-S98.

Savage SR, Joranson DE, Covington EC, et al.: Definitions related to the medical use of opioids: Evolution towards universal agreement. J Pain Symptom Manage. 2003; 26(1): 655-667.

Cohen MJM, Jasser S, Herron PD, et al.: Ethical perspectives: Opioid treatment of chronic pain in the context of addiction. Clin J Pain. 2002; 18: S99-S107.

Mott DA, Cline RR: Exploring generic drug use behavior: The role of prescribers and pharmacists in the opportunity for generic drug use and generic substitution. Med Care. 2002; 40(8): 662-674.

Druss BG, Marcus SC, Olfson M, et al.: Listening to generic prozac: Winners, losers, and sideliners. Health Affairs. 2004; 23(5): 210-216.

Inciardi JA: The War on Drugs III: The Continuing Saga of the Mysteries and Miseries of Intoxication, Addiction, Crime, and Public Policy. Boston, MA: Allyn and Bacon, 2002.

Inciardi J: The War on Drugs IV: The Continuing Saga of the Mysteries and Miseries of Intoxication, Addiction, Crime, and Public Policy, 4th ed. Boston: Pearson Education, 2008.

Eckholm E: Abuses are found in online sales of medication. New York Times, July 9, 2008.

Drug Topics: Top 200 generic drugs by units in 2007. Available at http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard//drugtopics/072008/491181/article.pdf. Accessed October 27, 2008.

Drug Topics: Top 200 generic drugs by units in 2007. Available at http://drugtopics.modernmedicine.com/drugtopics/data/ articlestandard//drugtopics/072008/491207/article.pdf. Accessed October 27, 2008.

Purdue Pharma L.P. v. Endo Pharms, Inc., 438 F3d 1123, 2006, 1135-1137.

Purdue Pharma L.P. v. Mallinckrodt, Inc., 1:2006cv13095, 2006.